Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Merck Sharp & Dohme LLC
Domenica Lorusso; Yang Xiang; Kosei Hasegawa; Giovanni Scambia; Manuel Leiva; Pier Ramos-Elias; Alejandro Acevedo; Vladyslav Sukhin; Noelle Cloven; Andrea J Pereira de Santana Gomes; Fernando Contreras Mejía; Ari Reiss; Ali Ayhan; Jung-Yun Lee; Valeriya Saevets; Flora Zagouri; Lucy Gilbert; Jalid Sehouli; Ekkasit Tharavichitkul; Kristina Lindemann; Roberta Lazzari; Chih-Long Chang; Rudolf Lampé; Hong Zhu; Ana Oaknin; Melissa Christiaens; Stephan Polterauer; Tomoka Usami; Kan Li; Karin Yamada; Sarper Toker; Stephen M Keefe; Sandro Pignata; Linda R Duska; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators